Stockscreener 앱 받기
1.54
0.00%
0.00
전일 마감가:
$1.54
열려 있는:
$1.53
하루 거래량:
62,650
Relative Volume:
0.12
시가총액:
$6.62M
수익:
-
순이익/손실:
$-7.50M
주가수익비율:
-0.3497
EPS:
-4.4035
순현금흐름:
$-6.14M
1주 성능:
-6.67%
1개월 성능:
-14.44%
6개월 성능:
-55.36%
1년 성능:
-89.31%
1일 변동 폭
$1.53
$1.61
1주일 범위
$1.51
$1.7499
52주 변동 폭
$1.3259
$13.70
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
명칭
Acurx Pharmaceuticals Inc
전화
917-533-1469
주소
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
1.54 | 6.62M | 0 | -7.50M | -6.14M | -4.4035 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acurx Pharmaceuticals Inc 주식(ACXP)의 최신 뉴스
Acurx Pharmaceuticals Inc (ACXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Institutional Confidence - TradingKey
Acurx Pharmaceuticals StockWednesday operations and pipeline snapshot - AD HOC NEWS
Acurx Pharmaceuticals Inc (ACXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inside Acurx’s 3.2Å look at a new antibiotic for drug‑resistant bacteria - Stock Titan
Acurx Pharmaceuticals Inc (ACXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Common Stock of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Warrants of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
ACXP Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress ContinuesEarnings Forecast Report - newsline.com
Acurx Pharmaceuticals (ACXP) upgraded to buy: Here's why - MSN
Acurx Pharmaceuticals (ACXP) Stock Slides Slightly as Price Tests SupportMcClellan Oscillator - newsline.com
ACXP Q1 2026 Earnings: Narrower-than-Expected Loss Delivers Positive SurpriseEarnings Trend Analysis - newsline.com
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why - Yahoo Finance
Acurx Pharmaceuticals stock (US00366D1037): Nasdaq price steady as investors eye valuation metrics - AD HOC NEWS
Acurx Pharmaceuticals (ACXP) Declines 6.74% as Stock Nears Key Support at $1.71Rip Sell Trade - newsline.com
Acurx Pharmaceuticals stock (US00366D1037): Analyst consensus points to high upside from low Nasdaq - AD HOC NEWS
ACXP Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Progress ContinuesDividend Growth Analysis - The Legal Advocate
ACXP Technical Analysis | Trend, Signals & Chart Patterns | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
Acurx Pharmaceuticals (ACXP) Holds Near Key Support as Small Decline Signals ConsolidationEqual Weight ETF - newsline.com
Acurx Pharmaceuticals (ACXP) Nudges Higher as Stock Approaches ResistanceChandelier Stop - thelegaladvocate.com
Acurx Pharmaceuticals Reports First Quarter 2026 Results, Highlights Ibezapolstat Phase 3 Trial for CDI Treatment - geneonline.com
ACXP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ACXP Q1 2026 Earnings: Narrowed Loss Surprises as Acurx Advances Lead CandidateGuidance Upgrade Report - newsline.com
ACXP Stock Price, Quote & Chart | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat - ACCESS Newswire
Earnings call transcript: Acurx Pharmaceuticals Q1 2026 sees EPS miss, stock dips - Investing.com Australia
Acurx outlines August first patient for 20-patient rCDI pilot as it weighs FDA one-trial path - MSN
Acurx Pharmaceuticals stock (US00366D1037): reverse split and price swings keep biotech in focus - AD HOC NEWS
Acurx (ACXP) Q1 2026 Earnings Transcript - AOL.com
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE) - The Globe and Mail
Maxim Group Maintains Acurx Pharmaceuticals(ACXP.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2026 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals (ACXP) registers 1.3M shares for Lincoln Park resale - Stock Titan
Acurx Pharmaceuticals (NASDAQ: ACXP) registers 1.65M resale shares - Stock Titan
Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
ACURX PHARMACEUTICALS ($ACXP) Releases Q1 2026 Earnings - Quiver Quantitative
Press Release: Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 Results and Provides Business Update - Moomoo
[EFFECT] Acurx Pharmaceuticals, Inc. SEC Filing - Stock Titan
TradingKey - TradingKey
Acurx Pharmaceuticals (ACXP) trims Q1 loss but flags going-concern risk - Stock Titan
ACXP Q1'26 Earnings: EPS estimate is (1.20) USD - TradingView
The growth story Acurx (ACXP) is not telling investors (Smart Money Outflows) 2026-05-08Crowd Entry Signals - newser.com
Acurx Pharmaceuticals Inc expected to post a loss of 63 cents a shareEarnings Preview - TradingView
Number of shareholders of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
1.65M ACXP warrant shares registered for resale by Acurx (NASDAQ: ACXP) - Stock Titan
Acurx (NASDAQ: ACXP) files S-1 to register 1.3M Lincoln Park resale shares - Stock Titan
Acurx Pharmaceuticals Inc (ACXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):